{
    "clinical_study": {
        "@rank": "164705", 
        "arm_group": [
            {
                "arm_group_label": "recombinant tissue plasminogen activator", 
                "description": "Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h."
            }, 
            {
                "arm_group_label": "rt-PA", 
                "description": "One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h."
            }
        ], 
        "brief_summary": {
            "textblock": "The time window for intravenous recombinant tissue plasminogen activator treatment in\n      ischemic stroke patients has been extended to 4.5h. Little is known about intravenous\n      recombinant tissue plasminogen activator use in the 3-4.5 hour time window among Chinese\n      stroke patients. This exploratory study was to describe the feasibility and outcome of\n      treatment with intravenous recombinant tissue plasminogen activator in the expanded time\n      window, and to offer suggestions for future clinical work in China."
        }, 
        "brief_title": "Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Favorable clinical outcome of intravenous recombinant tissue plasminogen activator was\n      assessed by absolute changes in the National Institute of Health Stroke Scale score at 24\n      hours and by the improvement of modified Rankin Scale score at discharge or 6-month\n      follow-up. The safety of intravenous recombinant tissue plasminogen activator was assessed\n      by the rate of mortality, intracerebral hemorrhage and other common complications.\n      Multivariate logistic regression models were used to evaluate factors associated with\n      favorable clinical outcome."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:stroke patients in the 3-4.5 hour time window -\n\n        Exclusion Criteria:stroke patients in more than 4.5 hour time window\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "stroke patients in the 3-4.5 hour time window"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01770197", 
            "org_study_id": "20090101"
        }, 
        "intervention": {
            "arm_group_label": [
                "recombinant tissue plasminogen activator", 
                "rt-PA"
            ], 
            "description": "IV rt-PA treatment", 
            "intervention_name": "IV rt-PA", 
            "intervention_type": "Drug", 
            "other_name": "rt-PA"
        }, 
        "intervention_browse": {
            "mesh_term": "Tissue Plasminogen Activator"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "China", 
            "Stroke", 
            "Thrombolytic therapy"
        ], 
        "lastchanged_date": "April 1, 2013", 
        "link": {
            "description": "Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window", 
            "url": "http://ClinicalTrials.gov"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Feasibility and Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window in China", 
        "overall_official": {
            "affiliation": "Wuhan General Hospital of Guangzhou Command", 
            "last_name": "Wuhan G H, High", 
            "role": "Study Chair"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Favorable clinical outcome of intravenous recombinant tissue plasminogen activator was assessed by absolute changes in the National Institute of Health Stroke Scale score at 24 hours and by the improvement of modified Rankin Scale score at discharge or 6-month follow-up", 
            "measure": "National Institute of Health Stroke Scale score and modified Rankin Scale", 
            "safety_issue": "Yes", 
            "time_frame": "Outcome measure will be assessed at 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01770197"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wuhan General Hospital of Guangzhou Military Command", 
            "investigator_full_name": "zhipeng xu", 
            "investigator_title": "Wuhan General Hospital of Guangzhou Military Command", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Wuhan General Hospital of Guangzhou Military Command", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wuhan General Hospital of Guangzhou Military Command", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2008", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "24 Weeks", 
        "verification_date": "January 2013"
    }
}